Companies
/Healthcare
Stereotaxis Inc
$1.01
▼ $0.04 (−3.81%) today
Markets closed · 9:43pm ET
STXS at a Glance
Valuation
- Market cap
- $101.2M
Profitability
- Revenue (TTM)
- $30.1M
- Profit margin
- -74.2%
- EPS (TTM)
- $-0.24
Price
- 52-week range
- $1 – $3
- Street target
- $3.00
Earnings
- Next report
- Nov 10, 2026
Headquartered in Saint Louis, MO Fiscal year ends December NYSE MKT: STXS stereotaxis.com
About Stereotaxis
Stereotaxis (NYSE: STXS) is a surgical robotics company focused on minimally invasive endovascular intervention. The company develops and commercializes robotic systems, instruments, and digital solutions for the interventional laboratory. Its product portfolio includes the GenesisX robotic system, Synchrony digital operating room systems, and MAGiC robotic catheters. Following its acquisition of Robocath, Stereotaxis now covers the full spectrum of endovascular procedures, extending beyond its core electrophysiology market. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions. Stereotaxis generates revenue from system sales and a recurring base of disposables, service, and accessories. Updated
Frequently Asked Questions
What does Stereotaxis do?
Stereotaxis (NYSE: STXS) is a surgical robotics company focused on minimally invasive endovascular intervention. The company develops and commercializes robotic systems, instruments, and digital solutions for the interventional laboratory.
What is the STXS stock price target?
The Wall Street consensus 12-month price target for STXS is $3.00.